Shanghai Medicilon Inc.

Equities

688202

CNE100003NQ8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
26.05 ^CNY	-2.32%		-8.76%	-61.90%

05-13	Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.	CI
05-12	Shanghai Medicilon Inc.'s Equity Buyback announced on November 13, 2023, has closed with 745,166 shares, representing 0.55% for CNY 39.98 million.	CI

Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.

May 13, 2024 at 05:00 pm

From April 1, 2024 to May 12, 2024, the company has repurchased 137,840 shares, representing 0.1% for CNY 5.08 million. With this, the company has completed the repurchase of 745,166 shares, representing 0.55% for CNY 39.98 million under the buyback announced on November 13, 2023.

Latest news about Shanghai Medicilon Inc.

Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.	05-13	CI
Shanghai Medicilon Inc.'s Equity Buyback announced on November 13, 2023, has closed with 745,166 shares, representing 0.55% for CNY 39.98 million.	05-11	CI
Shanghai Medicilon Inc. announces an Equity Buyback for CNY 20 million worth of its shares.	04-29	CI
Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-28	CI
Shanghai Medicilon Inc. authorizes a Buyback Plan.	04-25	CI
Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.	04-01	CI
China Healthcare Stocks Rally on Hopes for Government Support	03-14	DJ
Medicilon Appoints Dr. Qingcong Lin as President of Medicilon Usa Corp	03-11	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Medicilon Appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit	01-09	CI
Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.	01-02	CI
Shanghai Medicilon Inc.(SHSE:688202) dropped from Shanghai Stock Exchange Health Care Sector Index	12-08	CI
Shanghai Medicilon Inc. announces an Equity Buyback for CNY 40 million worth of its shares.	11-13	CI
Shanghai Medicilon Inc. authorizes a Buyback Plan.	11-12	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Fosun Health Capital Reaches Cooperation Agreement with Medicilon to Explore Innovative Drug Research and Development Together	31/07/23	CI
Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Shanghai Medicilon Logs 28.6% Jump in 2022 Profit	21/02/23	MT
Shanghai Medicilon Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/02/23	CI
Shanghai Medicilon Gets Securities Regulator's Nod to Issue Stocks	14/02/23	MT
Certain A Shares of Shanghai Medicilon Inc. are subject to a Lock-Up Agreement Ending on 6-NOV-2022.	05/11/22	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/10/22	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22/08/22	CI
Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI

Chart Shanghai Medicilon Inc.

Duration

Period

More charts

Company Profile

Shanghai Medicilon Inc is a China-based company mainly engaged in pre-clinical comprehensive research and development services of biomedicine. The Company is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The Company's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The Company provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.

Sector

Biotechnology & Medical Research

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Medicilon Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

26.05

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SHANGHAI MEDICILON INC.	-61.90%	494M
VERTEX PHARMACEUTICALS INCORPORATED	+16.02%	122B
REGENERON PHARMACEUTICALS, INC.	+19.29%	113B
ARGENX SE	+18.95%	26.49B
BIONTECH SE	-23.55%	19.4B
GENMAB A/S	-19.03%	16.24B
BEIGENE, LTD.	-20.15%	15.4B
WUXI APPTEC CO., LTD.	-46.14%	15.15B
SAREPTA THERAPEUTICS, INC.	+63.53%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.85%	13.52B

Bio Therapeutic Drugs